

## BICO releases preliminary revenue, EBITDA, and cash flow from operating activities for Q3, 2023

**BICO's revenue and EBITDA for Q3, 2023 is expected to be above market expectations in light of general industry development.**

The EBITDA is expected to amount to SEK 64.2m (1.8), corresponding to a margin of 10.9 per cent (0.3). The EBITDA for the quarter deviates mainly due to effects from structured cost control and right sizing as well as seasonal volume effect resulting in higher operational efficiency. The adjusted EBITDA is expected to amount to SEK 69.2m (18.1), corresponding to a margin of 11.8 per cent (3.3).

BICO expects the revenue for Q3 2023 to amount to SEK 587.2m (550.6) which corresponds to an increase of 6.6% per cent compared to the corresponding quarter previous year.

The cash flow from operating activities is expected to amount to SEK 3.6m (-15.6).

All amounts stated in this press release are preliminary and unaudited.

BICO's full financial performance will be presented in the interim report January – September 2023 released on November 14, 2023, at 07:00am CET, which means that the company is still in a quiet period.

**For further information, please contact:**

Erik Gatenholm, President & CEO, BICO Group AB

Telephone US: +1 (650) 515-5566

Telephone Sweden: +46 73 267 00 00

E-mail: [eg@bico.com](mailto:eg@bico.com)

Jacob Thordenberg, Chief Financial Officer, BICO Group AB

Phone: +46 73 534 88 84

E-mail: [jt@bico.com](mailto:jt@bico.com)

*This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-11-01 22:40 CET.*

**About BICO**

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. [www.bico.com](http://www.bico.com)

**Attachments**

[BICO releases preliminary revenue, EBITDA, and cash flow from operating activities for Q3, 2023](#)